Navellier & Associates Inc. Takes $5.27 Million Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Navellier & Associates bought a new stake of 7,795 IDEXX shares in Q4, valued at approximately $5.27 million.
• IDEXX beat Q1 estimates (EPS $3.47; revenue $1.14B, +14% YoY) and raised FY‑2026 guidance to an EPS range of $14.45–$14.90 and revenue of $4.7–$4.8B.
• About 87.8% of shares are held by institutions, but insiders sold roughly 45,957 shares (~$29.9M) last quarter; analysts show a "Moderate Buy" consensus with a $751 average target while valuation looks rich (P/E ~43, PEG ~3.4).

Navellier & Associates Inc. bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,795 shares of the company's stock, valued at approximately $5,274,000.

Several other hedge funds have also recently made changes to their positions in IDXX. Bank of New York Mellon Corp raised its position in IDEXX Laboratories by 41.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company's stock worth $1,313,992,000 after purchasing an additional 605,290 shares during the period. JPMorgan Chase & Co. raised its position in IDEXX Laboratories by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company's stock worth $555,802,000 after purchasing an additional 326,348 shares during the period. Zurich Insurance Group Ltd FI purchased a new stake in IDEXX Laboratories in the 3rd quarter worth about $143,730,000. Principal Financial Group Inc. raised its position in IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company's stock worth $840,638,000 after purchasing an additional 187,967 shares during the period. Finally, Invesco Ltd. raised its position in IDEXX Laboratories by 14.0% in the 3rd quarter. Invesco Ltd. now owns 1,320,263 shares of the company's stock worth $843,503,000 after purchasing an additional 161,782 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IDXX shares. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a "neutral" rating and a $650.00 price objective on the stock. Piper Sandler reduced their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research report on Monday, February 9th. UBS Group reduced their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 28th. Finally, BTIG Research reduced their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a research report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $751.00.

IDEXX Laboratories News Summary

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q1 results beat expectations: EPS of $3.47 topped consensus and revenue of $1.141B was above estimates; revenue grew ~14% year-over-year and margins improved — a clear operational beat. Read More.
• Positive Sentiment: Management lifted FY‑2026 guidance to an EPS range of $14.45–$14.90 and raised the revenue range to $4.7–$4.8B, reinforcing forward growth expectations and prompting a positive market reaction. Read More.
• Positive Sentiment: Analyst commentary highlights diagnostics growth and margin expansion — several outlets flagged the beat + upgraded tone, supporting near‑term upside sentiment. Read More.
• Neutral Sentiment: The full earnings call transcript and slide deck are available for deeper diligence; these provide detail on geographic/segment trends and capital allocation but are informational rather than market-moving by themselves. Read More.
• Neutral Sentiment: The company’s published earnings presentation offers line‑item detail on organic growth drivers (Companion Animal Group, diagnostics adoption, product launches). Useful for modeling revenue cadence. Read More.
• Negative Sentiment: Valuation and near‑term upside considerations: IDXX trades at a rich multiple (P/E ~43, PEG ~3.4) after an extended one‑year rally; some commentators question whether the stock has priced in much of the good news. Technicals also show the stock below its 200‑day average, suggesting mixed momentum. Read More.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 2,693 shares of the firm's stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the transaction, the executive vice president directly owned 19,899 shares of the company's stock, valued at approximately $13,163,984.46. This trade represents a 11.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the transaction, the director directly owned 648 shares in the company, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 45,957 shares of company stock valued at $29,862,109. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $562.97 on Wednesday. The firm has a market cap of $44.72 billion, a PE ratio of 43.07, a price-to-earnings-growth ratio of 3.42 and a beta of 1.58. The firm's 50 day simple moving average is $588.09 and its 200-day simple moving average is $650.80. IDEXX Laboratories, Inc. has a one year low of $465.00 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts' consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company's quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the company posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 14.54 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.